Novel agents for the treatment of mucositis

Journal of Supportive Oncology

Volumn 5, Issue 9 SUPPL. 4, 2007, Pages 33-39

  Posner, Marshall R ^a   Haddad, Robert I ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMIFOSTINE; BENZYDAMINE; ETIDRONIC ACID; FLUOROURACIL; FOLINIC ACID; GLUTAMINE; MELPHALAN; METHOTREXATE; PALIFERMIN; RECOMBINANT FIBROBLAST GROWTH FACTOR;

ANTIMICROBIAL THERAPY; CLINICAL TRIAL; CRYOTHERAPY; DRUG EFFICACY; ERYTHEMA; HUMAN; LOW LEVEL LASER THERAPY; MOUTH DISEASE; MOUTH HYGIENE; MOUTHWASH; PRURITUS; RASH; REVIEW; SINGLE DRUG DOSE; STOMATITIS; TASTE DISORDER; TONGUE DISEASE;

HUMANS; STOMATITIS;

EID: 35648943167     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Peterson DE. New strategies for management of oral mucositis in cancer patients. J Support Oncol 2006;2(suppl 1):9-13. [16499139]
2. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952. [15128894]
3. Pico JL, Avila-Garvato A,Naccachie P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998;3:446-451. [10388137]
4. Woo SB, Sonis ST, Monopoli MM, et al. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993;72:1612-1617. [8348492]
5. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit ofsimultaneous chemotherapy - results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-1171. [11483325]
6. Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol 2005;23:3008-3015. [15860857]
7. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201-2205. [11304772]
8. Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:1531-1539. [14508842]
9. National Cancer lnstitute. Common Terminology Criteria for adverse events. Available at: http://ctep.cancer.gov/reporting/ctc_v30.html. Accessed August 14, 2007.
10. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis T. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998;82:2275-2281. [9610710]
11. Bellin LA, Epstein JB, Rose-Ped A, et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-39. [10650895]
12. McGuire DB, Correa ME, Hohnson J, Wienandts P. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer 2006;14:541-547. [16775649]
13. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100(9 suppl):2026-2046. [15108223]
14. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2006,(2):CD000978. [16625538]
15. Schubert MM, Eduardo FP, Guthrie KA, et al. A phase III randomized double-blind placebo controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 2007; Mar 29; Epub ahead of print. [17393191]
16. Scarantino C, LeVeque F, Swann RS, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. J Support Oncol 2006;4:252-258. [16724649]
17. Barasch A, Elad S, Altman A, Damato K, Epstein J. Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support Care Cancer 2006;14:528-532. [16775648]
18. Lalla RV, Schubert MM, Bensadoun RJ, Keefe D. Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer 2006;14:558-565. [16565821]
19. Kim JH, Chu FC, Lakshmi V, Houde R. Benzydamine HCI, a new agent for the treatment of radiation mucositis of the oropharynx. Am J Clin Oncol 1986;9:132-134. [3521255]
20. Epstein JB, Silverman S Jr, Paggiarino DA, et al. Benzydamine HCI for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled trial. Cancer 2001;92:875-885. [11550161]
21. Sonis ST. A biological approach to mucositis. J Support Oncol 2004;2:21-36. [15330370]
22. FDA approves Kepivance for severe oral mucositis in cancer patients undergoing bone marrow transplant. Available at: http://www.amgen.com/ media/media_pr_detail.jsp?year=2004&releaseID=655220. Accessed July 23, 2007.
23. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-2598. [15602019]
24. Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006;24:5194-5200. [17075109]
25. Wagner W, Prott FJ, Shonekas KG. Amifostine: a radioprotector in locally advanced head and neck tumors. Oncol Rep 1998;5:1255-1257. [9683846]
26. Mell LK, Malik R, Komaki R, et al. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis. Int J Radiat Oncol Biol Phys 2007;68:111-118. [17289291]
27. Stokman MA, Wachters FM, Koopmans P, et al. Outcome of local application of amifostine (WRQ-1065) on epirubicin-induced oral mucositis: a phase II study. Anticancer Res 2004;24:3263-3267. [15510621]
28. Bensadoun RJ, Schubert MM, Lalla RV, Keefe D. Amifostine in the management of radiation-induced and chemo-induced mucositis. Support Care Cancer 2006;14:566-572. [16586122]
29. Lalla RV. Velafermin (CuraGen). Curr Opin Investig Drugs 2005;6:1179-1185. [16312140]
30. Schuster MW, Anaissie E, Hurd D, et al. Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single dose velafermin (CG53135-05) for the prevention of oral mucositis. J Clin Oncol 2006;24(1BS):6537.
31. Hirotani Y, Yamamoto K, Ikeda K, et al. Correlation between plasma glucagon-like peptide 2 levels and proliferative makers in small intestinal injury in rats induced by methotrexate administration. Bio Pharm Bull 2006;29:2327-2330. [17077541]
32. Boushey RP, Yusa B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001;61:687-693. [11212269]
33. Cockerham MB, Weinberger BB, Lerchie SB. Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother 2000;34:300-303. [10917373]
34. Peterson DE, Petit R. Phase III study: AES-14 in patients at risk for mucqsitis secondary to anthracycline-based chemotherapy. J Clin Oncol 2004;22(14S):8008.
35. RxKinetix completes its end of phase 2 meeting with the FDA for RK-0202 in oral mucositis and is moving into phase 3. Available at: www.newwire.com/cgi-binstories.pl?ACCT=104&STORY. Accessed July 22, 2007.
36. Zhao J, Huang L, Belmar N, Buelow R, Fong T. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res 2004,10:2851-2859. [15102694]
37. Clarke J, Butler R, Howarth G, Read L, Regester G. Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. Oral Oncol 2002;38:478-485. [12110343]
38. Freytes CO, Ratanatharathorn V, Taylor C. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clin Care Res 2004;10:8318-8324. [15623608]
39. Antin JH, Lee SJ, Neuberg D, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHS prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 2002;29:373-377. [11919725].